Established in 2002 by Edmund M. Dunn and his late wife Gloria support an outstanding leader in the fields of lung cancer research and thoracic surgical oncology.
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Co-Director, Immune Monitoring Facility
Dr. Hossein Borghaei’s laboratory concentrates on the development of new cancer treatments with an emphasis on the use of immunotherapy and monoclonal antibodies. They are capable of making new monoclonal antibodies against various cancer related targets and have recently received a patent for one such antibody. In collaboration with a number of other scientists at Fox Chase and as a result of laboratory based studies conducted at the Center, Dr. Borghaei has developed clinical trials that are ongoing for the treatment of patients with lung cancer. In addition to developing the next best treatment options as well as allowing patients access to potentially new and promising drugs through clinical trials, Dr. Borghaei is actively involved in lung cancer screening and research involving potential preventative measures with the hope of detecting lung cancer early and preventing recurrences of this disease.
Dr. Borghaei also benefits from several collaborations with scientists outside of Fox Chase with the aim of bringing newer and more effective immune based treatments to the clinic. This aids his efforts to examine patients’ tumors to try to learn why some patients respond to specific treatment while others don’t. Discovery of new or better ways of treating cancer is an important part of this research.